The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Valganciclovir Rowex 450 mg film coated tablet

450 milligram(s) Film-coated tablet

Rowex LtdPA0711/233/001

Main Information

Trade NameValganciclovir Rowex 450 mg film coated tablet
Active SubstancesValganciclovir hydrochloride
Strength450 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderRowex Ltd
Licence NumberPA0711/233/001

Group Information

ATC CodeJ05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB14 valganciclovir

Status

Authorised/WithdrawnAuthorised
Licence Issued09/01/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back